HeartFlow NXTOfficial

Cardiac

cardiac FFR-CT

Pivotal NXT trial of FFR-CT versus invasive FFR in stable coronary disease.

Condition
Blood flow / CAD
Participants
254
Journal
JACC
Date
2014-03

The HeartFlow NXT trial, published in March 2014, evaluated the performance of cardiac FFR-CT technology in patients with stable coronary artery disease. This pivotal study compared the non-invasive FFR-CT approach against invasive fractional flow reserve (FFR) measurements, a gold standard for assessing coronary artery blockages. Its inclusion in the Digital Health Study Tracker highlights its contribution to the evidence base for digital health interventions in cardiology.

What was studied

The HeartFlow NXT trial focused on the HeartFlow NXT system, a technology designed to non-invasively assess cardiac fractional flow reserve (FFR-CT). The study aimed to compare the diagnostic accuracy of this FFR-CT method with invasive FFR, which is traditionally performed in a catheterization laboratory. The condition under investigation was stable coronary artery disease (CAD), a common heart condition characterized by a buildup of plaque in the coronary arteries, potentially leading to reduced blood flow. The trial was designed as a pivotal study, indicating its importance in evaluating a new medical technology for potential clinical adoption. The comparison against invasive FFR suggests an intent to demonstrate the FFR-CT system’s ability to provide similar diagnostic information without the need for an invasive procedure.

Who was in the trial

The HeartFlow NXT trial included 254 participants. All participants had stable coronary artery disease. The directory record does not specify the geographical setting or specific recruitment criteria beyond the condition. The number of participants suggests a moderately sized clinical trial, often sufficient to establish initial efficacy and safety profiles for a new diagnostic tool. Without further details, it is not possible to elaborate on the demographics or specific clinical characteristics of the enrolled population. The focus on stable CAD implies that participants were likely undergoing evaluation for chest pain or other symptoms suggestive of coronary artery blockages, but not in an acute or emergency setting.

What the paper showed

The Digital Health Study Tracker indicates that the HeartFlow NXT trial was a “pivotal NXT trial of FFR-CT versus invasive FFR in stable coronary disease.” While the directory record and the provided PubMed link confirm the study’s existence and its publication in JACC in March 2014, neither explicitly details the specific findings or outcomes of the trial. Therefore, this article cannot report the exact results regarding the accuracy, sensitivity, specificity, or other performance metrics of the HeartFlow NXT system as determined by the study. The indexing of this study suggests that it contributed significant data to the understanding of FFR-CT technology in the context of stable coronary artery disease. Typically, pivotal trials aim to demonstrate that a new diagnostic tool is either non-inferior or superior to an existing standard, or that it provides valuable information for clinical decision-making. The absence of specific results in the provided structured facts means we can only infer the study’s intent rather than its conclusions.

How to read it

When reviewing a single study like the HeartFlow NXT trial, it’s crucial to understand its context within the broader scientific literature. A pivotal trial, by its nature, is often a key step in the development and potential regulatory approval of a new medical technology. However, no single study, regardless of its design or size, provides the complete picture. The findings of any trial should be considered alongside other research, including subsequent studies, meta-analyses, and real-world evidence. The Digital Health Study Tracker provides direct links to the original publication on PubMed or the journal’s website, which is essential for a comprehensive understanding. These links allow interested readers to access the full paper, including its detailed methodology, specific results, discussion of limitations, and authors’ conclusions. This level of detail is vital for clinicians, researchers, and policymakers to critically appraise the evidence and make informed decisions about the utility and implications of technologies like HeartFlow NXT in clinical practice. Relying solely on summaries, even authoritative ones, can omit nuances and important caveats present in the full publication.

Sources

This record aggregates public sources. Confirm figures with the linked originals before you rely on them.